159 related articles for article (PubMed ID: 24671610)
1. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy.
Oh DS; Koontz B; Freedland SJ; Gerber L; Patel P; Lewis S; Yoo DS; Oleson J; Salama JK
World J Urol; 2015 Jan; 33(1):93-7. PubMed ID: 24671610
[TBL] [Abstract][Full Text] [Related]
2. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
Gutt R; Tonlaar N; Kunnavakkam R; Karrison T; Weichselbaum RR; Liauw SL
J Clin Oncol; 2010 Jun; 28(16):2653-9. PubMed ID: 20421534
[TBL] [Abstract][Full Text] [Related]
3. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2004; 10(1):54-60. PubMed ID: 15000496
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.
Zaorsky NG; Buyyounouski MK; Li T; Horwitz EM
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e13-7. PubMed ID: 22652109
[TBL] [Abstract][Full Text] [Related]
6. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer.
Cuaron J; Pei X; Cohen GN; Cox BW; Yamada Y; Zelefsky MJ; Kollmeier MA
Brachytherapy; 2015; 14(2):179-84. PubMed ID: 25500364
[TBL] [Abstract][Full Text] [Related]
7. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer.
Stone NN; Stock RG; Unger P
J Urol; 2005 Mar; 173(3):803-7. PubMed ID: 15711273
[TBL] [Abstract][Full Text] [Related]
8. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
9. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
Potters L; Huang D; Fearn P; Kattan MW
Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
11. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
Galego P; Silva FC; Pinheiro LC
Int Braz J Urol; 2015; 41(2):353-9. PubMed ID: 26005979
[TBL] [Abstract][Full Text] [Related]
12. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
[TBL] [Abstract][Full Text] [Related]
14. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
Beyer DC; Thomas T; Hilbe J; Swenson V
Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
[TBL] [Abstract][Full Text] [Related]
15. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer.
Kattan MW; Potters L; Blasko JC; Beyer DC; Fearn P; Cavanagh W; Leibel S; Scardino PT
Urology; 2001 Sep; 58(3):393-9. PubMed ID: 11549487
[TBL] [Abstract][Full Text] [Related]
17. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy.
Potters L; Purrazzella R; Brustein S; Fearn P; Huang D; Leibel SA; Kattan MW
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):749-54. PubMed ID: 12788181
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.
Charret J; Baumann AS; Eschwege P; Moreau JL; Bernier V; Falk AT; Salleron J; Peiffert D
Brachytherapy; 2018; 17(6):888-894. PubMed ID: 30172752
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
